XL-184, a MET, VEGFR-2 and RET kinase inhibitor for the treatment of thyroid cancer, glioblastoma multiforme and NSCLC

IDrugs

Volumn 13, Issue 2, 2010, Pages 112-121

  Zhang, Ying ^a   Guessous, Fadila ^a   Kofman, Alex ^a   Schiff, David ^b   Abounader, Roger ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ERLOTINIB; PLACEBO; PROTEIN TYROSINE KINASE INHIBITOR; XL 184;

ANOREXIA; BLOOD BRAIN BARRIER; CANCER FATIGUE; CLINICAL TRIAL; CONFUSION; CONTROLLED CLINICAL TRIAL; CONVULSION; DIARRHEA; DIVERTICULITIS; DRUG BIOAVAILABILITY; DRUG DOSE ESCALATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG SYNTHESIS; ERYTHEMA; GAIT DISORDER; GLIOBLASTOMA; HUMAN; HYPERBILIRUBINEMIA; HYPERTENSION; HYPOPHOSPHATEMIA; HYPOTHYROIDISM; ILEUS; LUNG NON SMALL CELL CANCER; LYMPHOCYTOPENIA; MUCOSA INFLAMMATION; NAUSEA; NAUSEA AND VOMITING; NONHUMAN; PANCREAS CARCINOMA; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SKIN INFECTION; THYROID CANCER;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, MEDULLARY; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; GLIOBLASTOMA; HUMANS; LUNG NEOPLASMS; PROTEIN KINASE INHIBITORS; THYROID NEOPLASMS;

EID: 77749240452     PISSN: 13697056     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (64)

1. Suppression of glioblastoma angiogenicity and tumorigenicity by inhibition of endogenous expression of vascular endothelial growth factor. Cheng SY, Huang HJ, Nagane M, Ji XD, Wang D, Shih CC, Arap W, Huang CM, Cavenee WK PROC NATL ACAD SCI USA 1996 93 16 8502-8507
2. Exelixis announces broad alliance with GlaxoSmithKline to discover and develop novel therapeutics. Exelixis Inc PRESS RELEASE 2002 October 28
3. Exelixis and GlaxoSmithKline form broad alliance to discover and develop novel therapeutics. Exelixis Inc; GlaxoSmithKline plc PRESS RELEASE 2002 October 28
4. Exelixis amends collaboration with GlaxoSmithKline. Exelixis Inc PRESS RELEASE 2005 January 10
5. Exelixis fles IND application for anticancer compound XL184. Exelixis Inc PRESS RELEASE 2005 June 14
6. Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2. Kunkel P, Ulbricht U, Bohlen P, Brockmann MA, Fillbrandt R, Stavrou D, Westphal M, Lamszus K CANCER RES 2001 61 18 6624-6628
7. A phase I dose-escalation study of the safety and pharmacokinetics of XL184, a VEGFR and MET kinase inhibitor, administered orally to subjects with advanced malignancies. Kurzrock R, Camacho L, Hong D, Ng C, Janisch L, Ratain MJ, Salgia R EJC SUPPL 2006 4 12 Abs 405
8. MET amplifcation leads to geftinib resistance in lung cancer by activating ERBb3 signaling. Engelman JA, Zejnullahu K, Mitsudomi T, Song YC, Hyland C, Park JO, Lindeman N, Gale CM, Zhao XJ, Christensen J, Kosaka T et al SCIENCE 2007 316 5827 1039-1043
9. FLT3 mutations: Biology and treatment. Small D HEMATOLOGY (AM SOC HEMATOL EDUCATION PROGRAM) 2006 178-184
10. A phase 1 dose-escalation study of the safety and pharmacokinetics (PK) of XL184, a VEGFR and MET kinase inhibitor, administered orally to patients (pts) with advanced malignancies. Salgia R, Hong D, Sherman SI, Ng C, Frye J, Janish L, Ratain M, Kurzrock R MOL CANCER THER 2007 19 Abs A152
11. GlaxoSmithKline, via its center of excellence for external drug discovery, exercises its option to further develop and commercialize Exelixis' anti-cancer c-Met inhibitor XL880. Exelixis Inc PRESS RELEASE 2007 December 14
12. Exelixis initiates phase 1/2 trial of XL184 in patients with non-small cell lung cancer. Exelixis Inc PRESS RELEASE 2008 January 07
13. Phase I study of XL184, a RET, VEGFR2, and MET kinase inhibitor, in patients (pts) with advanced malignancies, including pts with medullary thyroid cancer (MTC). Salgia R, Sherman S, Hong DS, Ng CS, Frye J, Janisch L, Ratain MJ, Kurzrock R J CLIN ONCOL 2008 26 15S Abs 3522
14. Exelixis reaches agreement with FDA on special protocol assessment for XL184 phase 3 trial Exelixis Inc PRESS RELEASE 2008 June 16
15. NCT00704730: Phase 3 effcacy study of XL184 in adults with medullary thyroid cancer. WWW.CLINICALTRIALS.GOV 2008
16. NCT00704288: Study of XL184 in adults with glioblastoma multiforme. WWW.CLINICALTRIALS.GOV 2008
17. Exelixis notifes GlaxoSmithKline of proof-of-concept for XL184. Exelixis Inc PRESS RELEASE 2008 July 28
18. A phase I study of XL184, a MET, VEGFR2, and RET kinase inhibitor, administered orally to patients (pts) with advanced malignancies, including a subgroup of pts with medullary thyroid cancer (MTC). Kurzrock R, Sherman S, Hong D, Ng C, Frye J, Janisch L, Ratain MJ, Salgia R EORTC-NCI-AACR INT CONGRESS 2008 20 October 23 Abs 379
19. Targeting MET with XL184 to reverse EGFR tyrosine kinase inhibitor (TKI) resistance in NSCLC: Impact of preclinical studies on clinical trial design. Janne PA, Wax M, Leach J, Shankar G, Engelman J EORTC-NCI-AACR INT CONGRESS 2008 20 Abs 552
20. Exelixis retains rights to develop and commercialize XL184. Exelixis Inc PRESS RELEASE 2008 October 23
21. Bristol-Myers Squibb and Exelixis enter global collaboration on two novel cancer programs. Bristol-Myers Squibb Co PRESS RELEASE 2008 December 12
22. Bristol-Myers Squibb: In the pipeline. Bristol-Myers Squibb Co COMPANY WORLD WIDE WEB SITE 2009 January 15
23. A phase II study of XL184 in patients (pts) with progressive glioblastoma multiforme (GBM) in frst or second relapse. De Groot JF, Prados M, Urquhart T, Robertson S, Yaron Y, Sorensen AG, Norton A, Batchelor T, Drappatz J, Wen P J CLIN ONCOL 2009 27 15S Abs 2047
24. Use of neurovascular imaging in GBM patients (pts) to quantify early physiologic changes after treatment with XL184, an inhibitor of multiple receptor tyrosine kinases: Results from a phase II study. Sorensen AG, Jenning D, Wang M, Andronesi O, Chen P, Prados M, Wen P, Jackson E, Cha S, De Groot J J CLIN ONCOL 2009 27 15S Abs 2048
25. Correlative tumor molecular profling and plasma biomarker analysis in a phase II study of XL184 in patients with progressive or recurrent glioblastoma multiforme (GBM). DePrimo S, Wu B, Huang S, Bautista R, Cancilla B, Vysotskaia V, De Groot J, Prados M, Buller R, Wen P J CLIN ONCOL 2009 27 15S Abs 2049
26. Exelixis announces second quarter 2009 fnancial results. Exelixis Inc PRESS RELEASE 2009 July 30
27. Exelixis and Bristol-Myers Squibb report new phase 2 data for XL184 in patients with the most common and aggressive form of brain cancer. Exelixis Inc; Bristol-Myers Squibb Co PRESS RELEASE 2009 October 23
28. Preliminary results of a phase 1 study of XL184, a MET, VEGFR2 and RET kinase inhibitor (TKI), administered orally to patients with medulllary thyroid cancer (MTC). Kurzrock R, Sherman S, Pfster D, Cohen RB, Ball D, Hong D, Ng C, Frye J, Janisch L, Ratain MJ, Salgia R ACTA MED PORT 2009 Abs OP01
29. A phase I dose-escalation study of the safety and pharmacokinetics (PK) of XL184, a VEGFR and MET kinase inhibitor, administered orally to patients (pts) with advanced malignancies. Salgia R, Hong DS, Camacho LH, Ng CS, Janisch L, Ratain MJ, Kurzrock R J CLIN ONCOL 2007 25 18S Abs 14031
30. Scatter factor/hepatocyte growth factor in brain tumor growth and angiogenesis. Abounader R, Laterra J NEURO-ONCOLOGY 2005 7 4 436-451
31. Expression and localization of scatter factor/hepatocyte growth factor in human astrocytomas. Kunkel P, Muller S, Schirmacher P, Stavrou D, Fillbrandt R, Westphal M, Lamszus K NEURO-ONCOLOGY 2001 3 2 82-88
32. Prognostic signifcance of c-Met expression in glioblastomas. Kong DS, Song SY, Kim DH, Joo KM, Yoo JS, Koh JS, Dong SM, Suh YL, Lee JI, Park K, Kim JH et al CANCER 2009 115 1 140-148
33. Scatter factor hepatocyte growth factor expression enhances human glioblastoma tumorigenicity and growth. Laterra J, Rosen E, Nam M, Ranganathan S, Fielding K, Johnston P BIOCHEM BIOPHYS RES COMMUN 1997 235 3 743-747
34. Scatter factor promotes motility of human glioma and neuromicrovascular endothelial cells. Lamszus K, Schmidt NO, Jin L, Laterra J, Zagzag D, Way D, Witte M, Weinand M, Goldberg ID, Westphal M, Rosen EM INT J CANCER 1998 75 1 19-28
35. In vivo targeting of SF/HGF and c-Met expression via U1snRNA/ribozymes inhibits glioma growth and angiogenesis and promotes apoptosis. Abounader R, Lal B, Luddy C, Koe G, Davidson B, Rosen EM, Laterra J FASEB J 2002 16 1 108-110
36. Reversion of human glioblastoma malignancy by U1 small nuclear RNA/ribozyme targeting of scatter factor/hepatocyte growth factor and c-Met expression. Abounader R, Ranganathan S, Lal B, Fielding K, Book A, Dietz H, Burger P, Laterra J J NATL CANCER INST 1999 91 18 1548-1556
37. Inhibitors of vascular endothelial growth factor in cancer. Pourgholami MH, Morris DL CARDIOvASC HEMATOL AGENTS MED CHEM 2008 6 4 343-347
38. Dysregulated ret signaling in thyroid cancer. Castellone MD, Santoro M ENDOCRINOL METAB CLIN N AM 2008 37 2 363-374
39. Constitutive ret tyrosine kinase activation in hereditary medullary thyroid cancer: Clinical opportunities. Machens A, Lorenz K, Dralle H J INTERN MED 2009 266 1 114-125
40. Mechanisms of disease: Cancer targeting and the impact of oncogenic ret for medullary thyroid carcinoma therapy. Drosten M, Putzer BM NAT CLIN PRACT ONCOL 2006 3 10 564-574
41. Malignant gliomas in adults. Wen PY, Kesari S N ENGL J MED 2008 359 5 492-507
42. Comprehensive genomic characterization defnes human glioblastoma genes and core pathways. NATURE 2008 455 7216 1061-1068
43. Lung cancer. Herbst RS, Heymach JV, Lippman SM N ENGL J MED 2008 359 13 1367-1380
44. Emerging therapeutic targets in non-small cell lung cancer. Dy GK, Adjei AA PROC AM THORAC SOC 2009 6 2 218-223
45. Angiogenesis in the treatment of non-small cell lung cancer. Horn L, Sandler AB PROC AM THORAC SOC 2009 6 2 206-217
46. Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer. Maulik G, Kijima T, Ma PC, Ghosh SK, Lin J, Shapiro GI, Schaefer E, Tibaldi E, Johnson BE, Salgia R CLIN CANCER RES 2002 8 2 620-627
47. Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. Ma PC, Jagadeeswaran R, Jagadeesh S, Tretiakova MS, Nallasura V, Fox EA, Hansen M, Schaefer E, Naoki K, Lader A, Richards W et al CANCER RES 2005 65 4 1479-1488
48. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Stommel JM, Kimmelman AC, Ying HQ, Nabioullin R, Ponugoti AH, Wiedemeyer R, Stegh AH, Bradner JE, Ligon KL, Brennan C, Chin L et al SCIENCE 2007 318 5848 287-290
49. Anti-VEGF therapies for malignant glioma: Treatment effects and escape mechanisms. Miletic H, Niclou SP, Johansson M, Bjerkvig R EXPERT OPIN THER TARGETS 2009 13 4 455-468
50. A phase 2 study of XL184, an inhibitor of MET, VEGFR2, and RET, in patients with progressive glioblastoma multiforme. Wen P, Prados M, Chamberlain M, Cloughesy T, Drappatz J, Mikkelson T, Norden A, Weitzman R, Reardon D, Schiff D, de Groot J JOINT MEET SOC NEURO-ONCOL AANS/CNS SECT TUMORS 2009 Abs 599
51. Reduction of tumor invasiveness and metastasis and prolongation of survival of RIP-Tag2 mice after inhibition of VEGFR plus c-Met by XL184. Sennino B, Naylor RM, Tabruyn SP, You W-K, Aftab DT, McDonald DM AACR-NCI-EORTC INT CONGRESS 2009 21 Abs A13
52. Intracellular signal transduction pathway proteins as targets for cancer therapy. Adjei AA, Hidalgo M J CLIN ONCOL 2005 23 23 5386-5403
53. Medullary thyroid cancer: Therapeutic targets and molecular markers. Ball DW CURR OPIN ONCOL 2007 19 1 18-23
54. Therapeutic advances in the treatment of glioblastoma: Rationale and potential role of targeted agents Reardon DA, Wen PY ONCOLOGIST 2006 11 2 152-164
55. Targeting VEGF in cancer therapy. Donovan EA, Kummar S CURR PROBL CANCER 2006 30 1 7-32
56. Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: Current status and future directions. Morabito A, Piccirillo MC, Falasconi F, De Feo G, Del Giudice A, Bryce J, Di Maio M, De Maio E, Normanno N, Perrone F ONCOLOGIST 2009 14 4 378-390
57. Signal transduction via the stem cell factor receptor/c-Kit. Ronnstrand L CELL MOL LIFE SCI 2009 61 19-20 2535-2548
58. Suppression of Tie-1 in endothelial cells in vitro induces a change in the genome-wide expression profle refecting an infammatory function. Chan B, Sukhatme VP FEbS LETT 2009 583 6 1023-1028
59. Medullary thyroid carcinoma. Leboulleux S, Baudin E, Travagli JP, Schlumberger M CLIN ENDOCRINOL 2004 61 3 299-310
60. Glioblastoma multiforme: An emerging paradigm of anti-VEGF therapy. Reardon DA, Wen PY, Desjardins A, Batchelor TT, Vredenburgh JJ EXPERT OPIN bIOL THER 2008 8 4 541-553
61. Emerging role of epidermal growth factor receptor inhibition in therapy for advanced malignancy: Focus on NSCLC. Langer CJ INT J RADIAT ONCOL BIOL PHYS 2004 58 3 991-1002
62. Basic fbroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) levels, as prognostic indicators in NSCLC. Iwasaki A, Kuwahara M, Yoshinaga Y, Shirakusa T EUR J CARDIOTHORAC SURG 2004 25 3 443-448
63. MET as a target for treatment of chest tumors. Cipriani NA, Abidoye OO, Vokes E, Salgia R LUNG CANCER 2009 63 2 169-179
64. Lung cancer. Herbst RS, Heymach JV, Lippman SM N ENGL J MED 2008 359 13 1367-1380